
Please try another search
By Sam Boughedda
Investing.com — Galera Therapeutics Inc (NASDAQ:GRTX) shares jumped more than 144% in early Tuesday trading on the back of amended statistical significance data from its phase 3 trial of its drug to treat those undergoing radiation therapy.
The trial assessed the drug, avasopasem, in treating radiotherapy-induced tissue swelling in the mouth in patients with locally advanced head and neck cancer. The corrected data means the phase 3 trial achieved statistical significance on the primary endpoint of reduction in the incidence of this condition
The FDA has granted avasopasem with Breakthrough Therapy Designation (BTD) for the reduction swelling in the mouth induced by radiotherapy.
Galera had previously announced data that showed statistical significance on the primary endpoint was not achieved.
The company cited an error by the contract research organization. "Correction of this error resulted in improved p-values for the primary and secondary endpoints."
By Sabrina Valle HOUSTON (Reuters) - More than 200 people gathered in front of a federal courthouse in Houston, Texas on Friday, to voice their anger after the Supreme Court...
BERLIN (Reuters) - German sugar producer Suedzucker plans "significant" price hikes to offset rising costs and prepares to shift to coal as Russian gas supplies to Western Europe...
BERLIN (Reuters) - Lufthansa does not expect its global airline operations to return to normal until 2023 after staff shortages and booming demand amid the lifting of COVID-19...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.